Pharmasave helps Canadians kick nicotine in 2018
Pharmasave’s latest effort is focusing on helping Canadians quit nicotine. The company has encouraged Canadians to understand their personal health risks from smoking and get pharmacist support to help them become tobacco-free. Despite having one of the lowest smoking rates the world, smoking tobacco remains the leading cause of preventable death in Canada.
“There is still so much that we can and should do,” Pharmasave national director of pharmacy innovation Allison Nourse said. “Becoming tobacco-free is not easy and often takes numerous attempts. Consistent support and advocacy from a qualified healthcare professional to motivate and encourage behavioral changes related to smoking habits, while at the same time managing nicotine withdrawal symptoms, can increase the success rate of becoming tobacco-free. Regardless of how long a person has been smoking or using other forms of tobacco, Pharmasave pharmacists can help people become tobacco-free, improving their quality of life and increasing positive health outcomes.”
Pharmacists can counsel patients on available options for quitting, including medication and nicotine replacement products, as well as outline a step-by-step plan that includes strategies for handling cravings and managing withdrawal symptoms, the company said. Pharmasave said that studies have shown increased effectiveness from combining counseling and medication when helping individuals quit smoking.
Fresenius Kabi launches Velcade alternative
Fresenius Kabi has introduced its alternative of Takeda Oncology’s Velcade (bortezomib for injection). The Lake Zurich, Ill.-based company said that this addition to its oncology offerings is the first available alternative for intravenous use.
Fresenius Kabi’s product is available in a single-dose vial that contains 3.5 mg of lyophilized powder.
“Fresenius Kabi bortezomib is a cost-efficient product alternative for our customers and the patients they treat,” Fresenius Kabi USA president and CEO John Ducker said. “We are proud to offer an expansive oncology portfolio and will continue to develop these essential medicines”
Fresenius Kabi’s product is indicated to treat patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior treatment.
According to Takeda’s quarterly filings, Velcade has had U.S. sales of $60.2 million for the first two quarters of its fiscal year 2017. For the full fiscal year 2016, Takeda reported $112.9 million in U.S. sales for Velcade.
With strong flu season on horizon, Rite Aid urges flu shots
With the Centers for Disease Control and Prevention reporting widespread flu activity in 46 states, Rite Aid on Thursday urged people to get vaccinated against the flu if they haven’t already done so.
“With the CDC reporting widespread flu activity, health experts are predicting that the 2017-2018 flu season will be one of the worst in recent history,” stated Jocelyn Konrad, Rite Aid executive vice president of pharmacy.
[quote-from-article] “As we enter the peak of flu season, it’s not too late for people who haven’t been vaccinated against the flu to do so," she noted. "Though it takes two weeks to gain full protection against the flu, getting a flu shot as soon as possible is the single best way to fight the flu and the vaccine also helps to ease the severity and duration of symptoms if you come down with the flu.”
The CDC estimates the flu will infect 1-in-5 Americans this year.
With flu typically peaking between December and February, it’s possible for the flu season to run through March, meaning there is still time to get vaccinated.